Aliada Therapeutics
Aliada Therapeutics raises $1.4B Acquisition at $1.4B valuation
Quick Facts
Aliada Therapeutics: Acquisition Funding Round
Aliada Therapeutics has successfully raised $1.4B in Acquisition funding, reaching a valuation of $1.4B.
Company Overview
Blood-brain barrier platform acquired by AbbVie for CNS therapies
Funding Details
The Acquisition round was led by AbbVie (acquirer).
Company Information
- Headquarters: South San Francisco, CA
- Founded: 2018
- Employees: 90+
- Category: Biotech
Investment
Aliada Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- AbbVie (acquirer): Verified investor in Acquisition
Key Investors
About the Author
Related Company Reports
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...
HorizonStudio Raises $100M Growth to Transform Biotech
HorizonStudio has secured $100M Growth in funding to accelerate growth and innovation. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses...
StreamData Raises $15M Seed to Transform Biotech
StreamData has secured $15M Seed in funding to accelerate growth and innovation. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses...
